Skip to main content

Table 2 Results of single trial and direct comparison meta-analysis

From: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis

Treatment Study OS PFS ORR Overall SAEs RP Heterogeneity I2(%)
   HR(95%CI) HR(95% CI) OR(95% CI) OR(95% CI) OR(95% CI) OS PFS ORR SAE RP
EP vs PC [4,5,6] 0.85 (0.77–0.94) 0.66 (0.47–0.95) 1.0 (0.86–1.2) 1.2 (0.81–1.4) 0.48 (0.21–1.1) 0 0 59 0 27
PC-Cet vs PC [7] 1.1 (0.84–1.4) 0.99 (0.8–1.2) NR 1.2 (1.1–1.4) 0.56 (0.27–1.2)      
UP vs NP [8] 0.86 (0.35–2.1) 0.68 (0.35–1.3) 1.6 (0.53–5.1) 0.47 (0.29–0.76) 0.88 (0.12–6.6)      
NP vs PP [9] 1.7 (0.81–3.4) 1.6 (0.91–2.6) 1.4 (0.38–5.4) 1.9 (1.1–3.3) 5.7 (0.26–120.6)      
SP vs NP [10] 0.85 (0.49–1.5) 0.37 (0.15–0.94) 0.79 (0.31–2.0) 0.67 (0.50–0.88) 1.3 (0.32–5.0)      
NP vs EP [11] 0.93 (0.75–1.1) NR 1.3 (0.82–1.9) 0.91 (0.81–1.0) 0.86 (0.50–1.5)      
PC vs DP [12] 1.0 (0.33–3.3) 1.1 (0.48–2.3) 0.67 (0.23–2.0) 0.67 (0.39–1.2) 4.7 (0.22–101.6)      
PC vs GP [12] 0.77 (0.34–1.8) 0.67 (0.3–1.5) 1.1 (0.40–3.0) 0.80 (0.45–1.4) 1.9 (0.17–22.5)      
DP vs GP [12] 0.65 (0.28–1.5) 0.72 (0.36–1.5) 1.7 (0.56–4.9) 1.2 (0.70–2.0) 0.34 (0.01–8.8)      
MVP vs DP [13] 1.2 (0.8–1.7) 1.2 (0.89–1.7) 0.64 (0.33–1.2) 1.8 (1.5–2.0) 0.67 (0.24–1.8)      
SP vs DP [14] 0.81 (0.39–1.7) 1.1 (0.63–1.9) 1.2 (0.52–2.8) 0.49 (0.35–0.68) 0.10 (0.31–3.2)      
MVP vs IC [15] 0.98 (0.74–1.3) 0.89 (0.69–1.1) 1.5 (0.95–2.5) 1.8 (1.5–2.0) 0.33 (0.06–1.6)      
MVP vs PC [15] 0.95 (0.72–1.3) 1.1 (0.82–1.4) 1.2 (0.71–1.9) 2.1 (1.8–2.4) 0.33 (0.06–1.6)      
IC vs PC [15] 1.1 (0.79–1.4) 1.1 (0.86–1.5) 0.75 (0.47–1.2) 1.2 (1.0–1.4) 1.0 (0.31–3.2)      
PP vs EP [16] 0.98 (0.79–1.2) 0.86 (0.71–1.0) 1.1 (0.81–1.6) 0.96 (0.85, 1.1) 0.68 (0.21–2.2)      
PP vs PP-Cet [17] 1.1 (0.58–2.0) 1.1 (0.62–1.8) 1.3 (0.54–3.3) 0.99 (0.74–1.3) 1.1 (0.32–3.6)      
  1. Abbreviations: OS overall survival, PFS progression-free survival, ORR objective response rate, SAEs serious adverse events, RP radiation pneumonitis, HR hazard ratio, CI confidence interval, OR odds ratio, EP etoposide-cisplatin, PC paclitaxel-cisplatin/carboplatin, UP uracil/tegafur(UFT)-cisplatin, NP vinorelbine-cisplatin, PP pemetrexed-cisplatin/carboplatin, SP S-1-cisplatin, DP docetaxel-cisplatin, GP gemcitabine-cisplatin, MVP mitomycin-vindesine-cisplatin, IC irinotecan-carboplatin, Cet cetuximab, NR not reported
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us